

1 The association between prolonged SARS-CoV-2 symptoms and work outcomes

2

3 Arjun Venkatesh, MD, MBA, MHS^{1-2*}, Huihui Yu, PhD²; Caitlin Malicki, MPH¹; Michael Gottlieb,
4 MD³; Joann G. Elmore, MD, MPH⁴; Mandy J. Hill, DrPH, MPH⁵; Ahamed H. Idris, MD⁶; Juan Carlos
5 C. Montoy, MD, PhD⁷; Kelli N. O’Laughlin, MD, MPH⁸; Kristin L. Rising, MD, MSHP⁹⁻¹⁰; Kari A.
6 Stephens, PhD¹¹⁻¹²; Erica S. Spatz, MD, MHS^{13-14¶}; Robert A. Weinstein, MD^{15-16¶}for the INSPIRE
7 Group^

8

9 ¹Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, United States
10 of America

11

12 ²Center for Outcomes Research and Evaluation (CORE), Section of Cardiovascular Medicine, Yale
13 School of Medicine, Connecticut, United State of America

14

15 ³Department of Emergency Medicine, Rush University Medical Center, Chicago, Illinois, United States
16 of America

17

18 ⁴Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine
19 at the University of California, Los Angeles (UCLA), Los Angeles, California, United States of America

20

21 ⁵Department of Emergency Medicine, UTHealth Houston, Houston, Texas, United States of America

22

23 ⁶Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, Texas,
24 United States of America

25

26 ⁷Department of Emergency Medicine, University of California, San Francisco, San Francisco,
27 California, United States of America

28

29 ⁸Departments of Emergency Medicine and Global Health, University of Washington, Seattle,
30 Washington, United States of America

31

32 ⁹Department of Emergency Medicine, Sidney Kimmel Medical College, Thomas Jefferson University,
33 Philadelphia, Pennsylvania, United States of America

34

35 ¹⁰Center for Connected Care, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of
36 America

37

38 ¹¹Department of Family Medicine, University of Washington, Seattle, Washington, United States of
39 America

40
41 ¹²Department of Biomedical Informatics and Medical Education, University of Washington, Seattle,
42 Washington, United States of America

43
44 ¹³Department of Epidemiology, Yale School of Public Health, New Haven, Connecticut, United States
45 of America

46
47 ¹⁴Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, United
48 States of America

49
50 ¹⁵Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center,
51 Chicago, Illinois, United States of America

52
53 ¹⁶Department of Medicine, Cook County Hospital, Chicago, Illinois, United States of America

54
55
56
57

58 *Corresponding author

59 Email: arjun.venkatesh@yale.edu (AKV)

60

61 ¶These authors are co-senior authors.

62
63

64 ^Membership of the INSPIRE Group is provided in Appendix 1.

65 **Abstract**

66 While the early effects of the COVID-19 pandemic on the United States labor market are well-
67 established, less is known about the long-term impact of SARS-CoV-2 infection and Long COVID on
68 employment. To address this gap, we analyzed self-reported data from a prospective, national cohort
69 study to estimate the effects of SARS-CoV-2 symptoms at three months post-infection on missed
70 workdays and return to work. The analysis included 2,939 adults in the Innovative Support for Patients
71 with SARS-CoV-2 Infections Registry (INSPIRE) study who tested positive for their initial SARS-CoV-
72 2 infection at the time of enrollment, were employed before the pandemic, and completed a baseline and
73 three-month electronic survey. At three months post-infection, 40.8% of participants reported at least
74 one SARS-CoV-2 symptom and 9.6% of participants reported five or more SARS-CoV-2 symptoms.
75 When asked about missed work due to their SARS-CoV-2 infection at three months, 7.1% of
76 participants reported missing ≥ 10 workdays and 13.9% of participants reported not returning to work
77 since their infection. At three months, participants with ≥ 5 symptoms had a higher adjusted odds ratio
78 (aOR) of missing ≥ 10 workdays (2.96, 95% CI 1.81-4.83) and not returning to work (2.44, 95% CI 1.58-
79 3.76) compared to those with no symptoms. Prolonged SARS-CoV-2 symptoms were common,
80 affecting 4-in-10 participants at three-months post-infection, and were associated with increased odds of
81 work loss, most pronounced among adults with ≥ 5 symptoms at three months. Despite the end of the
82 Federal COVID-19 Public Health Emergency and efforts to “return to normal”, policymakers must
83 consider the clinical and economic implications of the COVID-19 pandemic on people’s employment
84 status and work absenteeism, particularly as data characterizing the numerous health and well-being
85 impacts of Long COVID continue to emerge. Improved understanding of risk factors for lost work time
86 may guide efforts to support people in returning to work.

87 **Introduction**

88 The COVID-19 pandemic has resulted in tremendous economic dislocation in labor markets, creating
89 historically volatile unemployment and reduced labor force participation rates due to unprecedented
90 occupational health stresses and work loss [1]. Even as labor markets have stabilized in most countries
91 including sustained periods of low unemployment [2], the economic impacts of the COVID-19
92 pandemic persist for many individuals as infections, hospitalizations and morbidity from SARS-CoV-2
93 infection continue.

94 Most prior research has examined the macroeconomic employment effects of the pandemic and
95 policy responses such as stay-at-home orders [3-4], with less investigation of the direct relationship
96 between SARS-CoV-2 illness and work. One small retrospective study conducted early in the pandemic
97 examining work outcomes among clinical cohorts reported that approximately half of individuals
98 hospitalized with SARS-CoV-2 were unable to return to work at six months [5]. A more recent study
99 using the US Current Population Survey found that work absences of up to one week due to acute
100 SARS-CoV-2 illness were associated with less labor force participation and more work absences one
101 year later, which is estimated to have reduced the US labor force by 500,000 people [6].

102 One possible mechanism for this long-term impact on employment is post-COVID conditions,
103 which include a wide range of physical and mental health consequences that are present at least four
104 weeks after SARS-CoV-2 infection [7-8]. Post-COVID conditions, often referred to as Long COVID,
105 affect nearly one-in-five adults with a history of SARS-CoV-2 infection [9] and may make returning to
106 work or seeking employment more difficult [10]. An unadjusted analysis of an international convenience
107 sample recruited via social media found that most individuals with SARS-CoV-2 symptoms beyond 28
108 days reported a reduced work schedule, suggesting a relationship between prolonged symptoms

109 following an acute SARS-CoV-2 infection and short-term work loss [11]. However, the prevalence of
110 Long COVID and its impact on work outcomes, such as return to work and missed workdays, is poorly
111 understood [12].

112 To address this gap, we sought to utilize data from the Innovative Support for Patients with
113 SARS-CoV-2 Infections Registry (INSPIRE) study to describe self-reported work outcomes related to
114 acute SARS-CoV-2 infection and the presence of symptoms at three months post-infection.

115

116 **Materials and methods**

117 **Study design**

118 INSPIRE is a previously described prospective study designed to assess long-term symptoms and
119 outcomes among persons with COVID-like illness who tested positive versus negative for SARS-CoV-2
120 at study enrollment [13]. Participants were enrolled virtually or in-person across eight study sites,
121 including Rush University (Chicago, Illinois), Yale University (New Haven, Connecticut), the
122 University of Washington (Seattle, Washington), Thomas Jefferson University (Philadelphia,
123 Pennsylvania), the University of Texas Southwestern (Dallas, Texas), the University of Texas, Houston
124 (Houston, Texas), the University of California, San Francisco (San Francisco, California) and the
125 University of California, Los Angeles (Los Angeles County, California). Inclusion criteria included age
126 ≥ 18 years, fluency in English or Spanish, self-reported symptoms suggestive of acute SARS-CoV-2
127 infection at time of testing (e.g., fever, cough), and testing for SARS-CoV-2 with an FDA-
128 approved/authorized molecular or antigen-based assay within the preceding 42 days. Exclusion criteria
129 included inability to provide consent, being lawfully imprisoned, inability of the study team to confirm
130 the result of the index diagnostic test for SARS-CoV-2, having a previous SARS-CoV-2 infection >42

131 days before enrollment, and lacking access to an internet-connected device (e.g., smartphone, tablet,
132 computer) for electronic survey completion. Participants with a positive SARS-CoV-2 test (COVID-
133 positive) and a negative SARS-CoV-2 test (COVID-negative) were recruited in a 3:1 ratio. Following
134 electronic consent, participants completed a baseline survey and follow-up surveys every three months
135 for up to 18 months post-enrollment, although only baseline and three-month follow-up surveys were
136 included in this secondary analysis. The three-month survey was sent 76 days following enrollment,
137 which was up to 118 days after the positive SARS-CoV-2 test, and participants had a 28-day window to
138 complete the three-month survey.

139

140 **Surveys**

141 The baseline and three-month surveys included a variety of questions regarding sociodemographics,
142 SARS-CoV-2 symptoms and overall health to assess long-term symptoms and outcomes related to
143 COVID-like illness. To establish baseline employment status, the baseline survey asked, “Were you
144 employed before the coronavirus outbreak?”, with the following response options: Yes; No. To establish
145 return to work status following a SARS-CoV-2 infection, the three-month survey asked, “Did you return
146 to work after your COVID-19 like symptoms?”, with the following response options: Yes, full-time;
147 Yes, part-time or modified work; No; Not applicable. To establish workdays missed due to SARS-CoV-
148 2 infection, the three-month survey asked, “Since before you had COVID-19 like symptoms, how many
149 workdays or weeks did you miss because of health reasons?”, with the following response options: I
150 don’t work; 0-5 workdays; 6-10 workdays; 10-20 workdays; up to 4 weeks.

151 To assess SARS-CoV-2 symptoms at the time of survey completion, the baseline and three-
152 month surveys asked, “Do you currently have any of the following ongoing symptoms? (Select all that
153 apply)”, with the following response options: fever; feeling hot or feverish; chills; repeated shaking with

154 chills; more tired than usual; muscle aches; joint pains; runny nose; sore throat; a new cough, or
155 worsening of a chronic cough; shortness of breath; wheezing, pain or tightness in your chest;
156 palpitations; nausea or vomiting; headache; hair loss; abdominal pain; diarrhea (>3 loose/looser than
157 normal stools/24 hours); decreased smell or change in smell; decreased taste or change in taste; none of
158 the above.

159

160 **Analysis**

161 This analysis was restricted to COVID-positive participants who responded “yes” to being employed
162 prior to the pandemic on the baseline survey and completed the three-month survey. Unadjusted
163 comparisons in baseline characteristics and outcomes were made using chi-square tests among groups
164 with different numbers of symptoms (0, 1-2, 3-4, ≥ 5 symptoms). We examined the association of the
165 number of symptoms at three-months with return to work and health-related work absenteeism (days
166 missed ≥ 10) between enrollment and three-months using logistic regression models adjusting for age,
167 gender, race, ethnicity, income, marital status, education, clinical comorbidity count, and SARS-CoV-2
168 variant time period [14]. Covariates were included in the model based on existing literature and
169 unadjusted tests on the significance of association with outcomes. To categorize missed workdays, we
170 established a cutoff of greater than or equal to ten days based on the original design of survey response
171 options. All statistics and data analysis were performed in SAS 9.4.

172

173 **Results**

174 **Survey Completion**

175 Among 8,950 individuals who completed informed consent between December 2020 and August 2022,
 176 6,049 were eligible for the three-month survey (**Figure 1**). A total of 4,588 participants completed the
 177 three-month survey, with survey completion rates varying slightly between the COVID-positive (77%)
 178 and COVID-negative (71%) groups. Among COVID-positive three-month survey respondents only
 179 (n=3,533), we analyzed data from the 2,939 participants (83.2%) who responded “yes” to being
 180 employed prior to the pandemic on the baseline survey.

181

182 Participant Characteristics

183 The mean age was 40 years (SD 12.6), 64.1% were female, 69.5% were white, 61.2% were vaccinated
 184 for SARS-CoV-2 before index test, and 3.8% were hospitalized for SARS-CoV-2 infection. 1,732
 185 (59.2%) and 282 (9.6%) reported 0 and ≥ 5 symptoms at three months, respectively (**Table 1**).

Characteristic n (%)	Total n=2928*	Number of Symptoms at 3 months (n, %)				p-value
		0 (1732, 59.2)	1-2 (677, 23.1)	3-4 (237, 8.1)	≥ 5 (282, 9.6)	
Age						0.306
18-34	1210 (41.3)	750 (43.7)	269 (40)	87 (37)	104 (37)	
35-49	1019 (34.8)	581 (33.8)	249 (37.1)	88 (37.4)	101 (35.9)	
50-64	548 (18.7)	314 (18.3)	121 (18)	49 (20.9)	64 (22.8)	
65+	129 (4.4)	73 (4.2)	33 (4.9)	11 (4.7)	12 (4.3)	
Missing^	22 (0.8)					
Gender						<.001
Female	1878 (64.1)	1052 (62.5)	458 (69.4)	165 (72.7)	203 (73.3)	
Male	930 (31.8)	612 (36.4)	191 (28.9)	58 (25.6)	69 (24.9)	
Transgender/Non-Binary/Other	39 (1.3)	19 (1.1)	11 (1.7)	4 (1.8)	5 (1.8)	
Missing^	81 (2.8)					
Ethnicity						0.024
Non-Hispanic	2485 (84.9)	1494 (87.9)	565 (85)	190 (81.5)	236 (85.5)	
Hispanic	388 (13.3)	205 (12.1)	100 (15)	43 (18.5)	40 (14.5)	
Missing^	55 (1.8)					
Race						<.001
American Indian/Alaskan Native	18 (0.6)	11 (0.7)	2 (0.3)	1 (0.4)	4 (1.4)	
Asian/Native Hawaiian/Pacific Islander	389 (13.3)	249 (14.7)	92 (14)	24 (10.5)	24 (8.7)	
Black	189 (6.5)	103 (6.1)	32 (4.9)	26 (11.4)	28 (10.1)	
White	2036 (69.5)	1217 (72)	474 (72.3)	148 (64.9)	197 (71.1)	

Other	220 (7.5)	111 (6.6)	56 (8.5)	29 (12.7)	24 (8.7)	
Missing^	76 (2.6)					
Education						<.001
Less than High school	24 (0.8)	11 (0.6)	5 (0.8)	4 (1.7)	4 (1.4)	
High school graduate	129 (4.4)	64 (3.8)	28 (4.2)	20 (8.7)	17 (6.1)	
Some College	355 (12.1)	185 (10.9)	75 (11.3)	31 (13.4)	64 (22.9)	
2-year degree	189 (6.5)	88 (5.2)	47 (7.1)	27 (11.7)	27 (9.6)	
4-year degree	1018 (34.8)	621 (36.6)	228 (34.4)	74 (32)	95 (33.9)	
More than 4-year degree	1156 (39.5)	728 (42.9)	280 (42.2)	75 (32.5)	73 (26.1)	
Missing^	57 (1.9)					
Marital Status						<.001
Married	1665 (56.9)	994 (57.4)	397 (58.7)	124 (52.8)	150 (53.2)	
Divorced/Widowed/Separated	253 (8.6)	123 (7.1)	58 (8.6)	37 (15.7)	35 (12.4)	
Never married	1007 (34.4)	615 (35.5)	221 (32.7)	74 (31.5)	97 (34.4)	
Missing^	3 (0.1)					
Annual Family Income						<.001
<10,000	77 (2.6)	45 (2.6)	14 (2.1)	5 (2.1)	13 (4.6)	
10,000-34,999	271 (9.3)	137 (7.9)	59 (8.7)	36 (15.2)	39 (13.8)	
35,000-49,999	285 (9.7)	132 (7.6)	79 (11.7)	31 (13.1)	43 (15.2)	
50,000-74,999	391 (13.4)	217 (12.5)	102 (15.1)	32 (13.5)	40 (14.2)	
75,000+	1751 (59.8)	1105 (63.8)	393 (58.1)	125 (52.7)	128 (45.4)	
Prefer not to answer	152 (5.2)	96 (5.5)	29 (4.3)	8 (3.4)	19 (6.7)	
Missing^	1 (0)					
Health Insurance						<.001
Private	2378 (81.2)	1460 (84.3)	549 (81.1)	177 (74.7)	192 (68.1)	
Public	383 (13.1)	188 (10.9)	89 (13.1)	38 (16)	68 (24.1)	
Private and public	68 (2.3)	40 (2.3)	11 (1.6)	11 (4.6)	6 (2.1)	
None	99 (3.4)	44 (2.5)	28 (4.1)	11 (4.6)	16 (5.7)	
Housing						0.450
Unstable housing	25 (0.9)	12 (0.7)	6 (0.9)	4 (1.7)	3 (1.1)	
Stable housing	2898 (99)	1719 (99.3)	671 (99.1)	233 (98.3)	275 (98.9)	
Missing^	5 (0.1)					
Tobacco Use						<.001
Any tobacco use	385 (13.1)	221 (12.8)	68 (10)	40 (16.9)	56 (19.8)	
No tobacco use	2541 (86.8)	1510 (87.2)	609 (90)	196 (83.1)	226 (80.1)	
Missing^	2 (0.1)					
Comorbidities						
Asthma	331 (11.3)	156 (9.1)	78 (11.6)	44 (19)	53 (19.6)	<.001
Hypertension	330 (11.3)	175 (10.2)	72 (10.7)	34 (14.7)	49 (18.1)	<.001
Diabetes	118 (4)	69 (4)	27 (4)	13 (5.6)	9 (3.3)	0.613
Obesity	763 (26.1)	397 (23.2)	179 (26.7)	93 (40.3)	94 (34.8)	<.001
Emphysema/COPD	47 (1.6)	22 (1.3)	16 (2.4)	3 (1.3)	6 (2.2)	0.219
Heart conditions	28 (1)	16 (0.9)	6 (0.9)	2 (0.9)	4 (1.5)	0.844
Kidney disease	6 (0.2)	2 (0.1)	1 (0.1)	0 (0)	3 (1.1)	0.008
Liver disease	15 (0.5)	4 (0.2)	6 (0.9)	2 (0.9)	3 (1.1)	0.075

Missing [^]	44 (1.5)					
COVID-19 Testing Location						<.001
At home	469 (16)	312 (18.1)	117 (17.3)	19 (8)	21 (7.5)	
Walk in clinic	361 (12.3)	198 (11.5)	73 (10.8)	34 (14.3)	56 (20.1)	
Emergency department	73 (2.5)	29 (1.7)	14 (2.1)	11 (4.6)	19 (6.8)	
Hospital	218 (7.4)	121 (7)	51 (7.6)	22 (9.3)	24 (8.6)	
Drive up testing site	1621 (55.4)	974 (56.4)	375 (55.6)	131 (55.3)	141 (50.5)	
Other	177 (6)	94 (5.4)	45 (6.7)	20 (8.4)	18 (6.5)	
Missing [^]	9 (0.4)					
Hospitalization for SARS-CoV-2						<.001
Not hospitalized	2779 (94.9)	1678 (97.7)	641 (95.7)	219 (94.8)	241 (89.3)	
Hospitalized	110 (3.8)	40 (2.3)	29 (4.3)	12 (5.2)	29 (10.7)	
Missing [^]	39 (1.3)					
Vaccination Status before SARS-CoV-2 Infection						<.001
Unvaccinated	535 (18.3)	288 (21.2)	103 (19.7)	46 (24)	98 (38.4)	
Vaccinated	1792 (61.2)	1070 (78.8)	419 (80.3)	146 (76)	157 (61.6)	
Missing [^]	601 (20.5)					

186

187 **Work Outcomes**

188 For missed workdays at three months post-infection, 197 participants (6.7%) missed ≥ 10 workdays,
 189 2546 participants (87.0%) missed < 10 workdays, 184 participants (6.3%) were not applicable (i.e. did
 190 not have work), and 1 participant (0.0%) was missing a response. For return to work at three months
 191 post-infection, 386 participants (13.2%) did not return to work, 2388 participants (81.6%) returned to
 192 work, and 154 participants (5.3%) were missing responses. The unadjusted bivariate analyses showed
 193 that participants with ≥ 5 symptoms had significantly higher odds of missing ≥ 10 workdays (18.8%) than
 194 participants with fewer (7.6-12.7%) or no symptoms (4.5%) at three months. Similarly, the unadjusted
 195 bivariate analyses showed that participants with ≥ 5 symptoms were significantly more likely to not
 196 return to work (27.8%) compared to participants with fewer (15.1-16.3%) or no symptoms (10.5%) at
 197 three months.

198 After adjusting for participants' sociodemographic and history of clinical conditions, participants
 199 with ≥ 5 symptoms had the greatest odds of missing ≥ 10 workdays and not returning to work compared

200 to those with fewer or no symptoms at three months (**Figure 2**). For participants with ≥ 10 missed
201 workdays, there was a “dose-response” relation to number of symptoms: Compared to participants with
202 no symptoms at three months, the odds of missing ≥ 10 workdays was two times higher in participants
203 with 3-4 symptoms (adjusted odds ratio [aOR]=1.94, 95% CI: 1.08-3.49) and nearly three times higher
204 in participants with ≥ 5 symptoms (aOR=2.96, 95% CI: 1.81-4.83). The difference in odds of missed
205 workdays was not significant among participants with 1-2 symptoms compared to those with no
206 symptoms at three months (aOR=1.58, 95% CI: 0.998-2.49). Compared to participants with no
207 symptoms at three months, the odds of not returning to work were higher in participants with ≥ 5
208 symptoms (aOR=2.44, 95% CI: 1.58-3.76) and in participants with 1-2 symptoms (aOR=1.74, 95% CI:
209 1.23-2.47). The difference in odds of not returning to work was not significant among participants with
210 3-4 symptoms compared to those with no symptoms at three months (aOR=1.25, 95% CI: 0.73-2.14).

211

212 **Discussion**

213 The presence of SARS-CoV-2 symptoms three months after acute infection was pervasive and was
214 associated with greater odds of work loss at three months in a prospective registry of people with an
215 initial SARS-CoV-2 infection. This association was especially pronounced among adults with a greater
216 symptom burden (≥ 5 symptoms) at three months, who experienced two to three-fold increased risk of
217 substantial missed workdays and not returning to work compared to adults whose symptoms resolved by
218 three months.

219 Our work extends prior literature in a few notable ways. First, by capturing clinical information
220 beyond the acute SARS-CoV-2 infection period and including primarily adults with milder disease, the
221 relationships identified in the INSPIRE registry are likely more generalizable to working U.S. adults
222 than prior work in more limited populations. In addition, because the INSPIRE registry includes baseline

223 and longer-term follow up data, this analysis supports temporally connecting persistent SARS-CoV-2
224 symptoms to long-term work outcomes. Second, the consistent relationship between increased three-
225 month symptom burden and worse work outcomes further bolsters the likelihood that health effects of
226 post-COVID conditions are sufficient to explain the well-documented relationship between health and
227 work status. Lastly, the broad enrollment period of the INSPIRE registry between December 2020 and
228 August 2022 demonstrates the durability of these findings despite the likely heterogeneous effects of
229 SARS-CoV-2 infection upon work alongside evolving variants, severity of disease, vaccination and
230 treatment.

231 Given high SARS-CoV-2 vaccination rates (77% among participants with non-missing data) and
232 the mild disease course observed in this cohort, the magnitude of work loss is striking. Extrapolating to
233 208 million adults working in the U.S., of whom at least 42% are estimated to have been infected with
234 SARS-CoV-2 as of May 2022 [15], our data suggest that symptomatic SARS-CoV-2 infection may have
235 contributed to over 12.9 million individuals not returning to work within three months of infection, of
236 whom 2.4 million may have post-covid conditions. Given the disproportionate burden of SARS-CoV-2
237 infection observed among workers in public-facing industries, such as education and healthcare, the
238 economic impacts of Long COVID may be disproportionately distributed across the nation [16].

239 As with all studies, this analysis has limitations. First, estimates may overattribute work loss due
240 to SARS-CoV-2 as our analysis did not include COVID-negative participants and other pandemic-
241 related causes. Second, our analyses considered each symptom equally, which may not capture nuanced
242 relationships between symptom type, symptom severity and work outcomes. Third, survey questions and
243 responses were developed iteratively in response to the changing landscape of the pandemic, and
244 analysis was limited by survey design and available data. Lastly, there is risk of residual confounding as

245 we were not able to adjust for all covariates, such as disability, which were found correlated with the
246 covariates included and outcomes.

247

248 **Conclusion**

249 Findings suggest that prolonged SARS-CoV-2 symptoms are common, affecting 4-in 10 participants at
250 three months post-infection and are associated with increased odds of work loss, with the most
251 pronounced work loss association among adults with ≥ 5 at three months. As data characterizing the
252 numerous health and well-being impacts of Long COVID emerge, despite efforts to “return to normal,”
253 policymakers must consider the clinical and economic implications of the COVID-19 pandemic on
254 people’s employment status and work absenteeism and strategies for reducing absenteeism.

255

256 **Acknowledgements**

257 We would like to thank the California Department of Public Health, CTSI COVID Clinical Research
258 Steering Committee, CTSI Office of Clinical Research Patient Navigation Team, and Bioinformatics
259 Program Public Health Seattle King County for their assistance with participant recruitment. We would
260 also like to thank the University of Washington Institute of Translational Health Sciences (ITHS) for
261 support of the REDCap instance and for biomedical informatics resources used by the UW Clinical Core
262 and Enrolling Site to enable study recruitment, which is funded by the National Center for Advancing
263 Translational Sciences of the National Institutes of Health under award number UL1TR002319.

264

265 **References**

266

- 267
268
269
270
271
272
273
1. The Labor Supply Rebound from the Pandemic. The White House. 2023 Apr 17. Available from: <https://www.whitehouse.gov/cea/written-materials/2023/04/17/the-labor-supply-rebound-from-the-pandemic/>
 2. Maria Ramos. Employment recovery continues in 2021, with some industries reaching or exceeding their prepandemic employment levels," Monthly Labor Review, U.S. Bureau of Labor Statistics, May 2022, <https://doi.org/10.21916/mlr.2022.15>
 - 274
275
276
277
 3. Bairoliya N, Imrohoroglu A. Macroeconomic consequences of stay-at-home policies during the COVID-19 pandemic. Eur Econ Rev. 2023;152:104266.
 - 278
279
280
281
 4. Béland, Louis-Philippe and Brodeur, Abel and Brodeur, Abel and Wright, Taylor, Covid-19, Stay-at-Home Orders and Employment: Evidence from CPS Data. IZA Discussion Paper No. 13282, Available at SSRN: <https://ssrn.com/abstract=3608531> or <http://dx.doi.org/10.2139/ssrn.3608531>
 - 282
283
284
285
 5. Frontera JA, Yang D, Lewis A, Patel P, Medicherla C, Arena V, et al. A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications. J Neurol Sci. 2021;426:117486.
 - 286
287
288
 6. Goda GS, Soltas EJ. The impacts of Covid-19 absences on workers. J Public Econ. 2023;222:104889.
 - 289
290
291
 7. Post-COVID Conditions: Information for Healthcare Providers. Centers for Disease Control and Prevention: 2023 Sep 11. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html>
 - 292
293
294
295
 8. Post COVID-19 condition (Long COVID). World Health Organization: 2022 Dec 7. Available from: <https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition>
 - 296
297
298
299
 9. Nearly One in Five American Adults Who Have Had COVID-19 Still Have "Long COVID". Centers for Disease Control and Prevention; 2022 Jun 22. Available from: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm
 - 300
301
 10. Ziauddeen N, Pantelic M, O'Hara ME, Hastie C, Alwan NA. Impact of long COVID-19 on work: a co-produced survey. Lancet. 2023;402 Suppl 1:S98.
 - 302
303
304
305
306
 11. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.

- 307 12. Shining a Light on Long COVID: An Analysis of Workers' Compensation Data. The New York
308 State Insurance Fund. 2023 Jan 24. Available from: [https://ww3.nysif.com/-](https://ww3.nysif.com/-/media/Files/NYSIF_Publications/PDF/NYSIFLongCOVIDStudy2023.ashx)
309 [/media/Files/NYSIF_Publications/PDF/NYSIFLongCOVIDStudy2023.ashx](https://ww3.nysif.com/-/media/Files/NYSIF_Publications/PDF/NYSIFLongCOVIDStudy2023.ashx)
- 310
- 311 13. O'Laughlin KN, Thompson M, Hota B, Gottlieb M, Plumb ID, Chang AM, et al. Study protocol for
312 the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE): A
313 longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection. PLoS One.
314 2022;17(3):e0264260.
- 315
- 316 14. Gottlieb M, Wang RC, Yu H, Spatz ES, Montoy JCC, Rodriguez RM, et al. Severe Fatigue and
317 Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2
318 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective
319 Cohort Study. Clin Infect Dis. 2023;76(11):1930-41.
- 320
- 321 15. Akinbami LJ, Kruszon-Moran D, Wang CY, Storandt RJ, Clark J, Riddles MK, et al. SARS-CoV-2
322 Serology and Self-Reported Infection Among Adults - National Health and Nutrition Examination
323 Survey, United States, August 2021-May 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1522-
324 5.
- 325
- 326 16. Kromydas T, Demou E, Edge R, Gittins M, Katikireddi SV, Pearce N, et al. Occupational
327 differences in the prevalence and severity of long-COVID: analysis of the Coronavirus (COVID-19)
328 Infection Survey. Occupational and Environmental Medicine [Internet]. 2023 Oct 1;80(10):545-52.

329

330 **Supporting Information**

331 **S1 Fig. This is the S1 Fig Title.** This is the S1 Fig legend.

332 **S2 Fig. This is the S2 Fig Title.** This is the S2 Fig legend.

333 **S1 Table. This is the S1 Table Title.** This is the S1 Table legend.

334 **S1 File. This is the S1 File Title.** This is the S1 File author group.




Figure 2




Figure 1